Expression of atrial and brain natriuretic peptides and their genes in hearts of patients with cardiac amyloidosis

Department of Internal Medicine, Hyogo Prefectural Amagasaki Hospital, Japan.

OBJECTIVES: We investigated the expression of atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) and their genes in the hearts of patients with cardiac amyloidosis and those with isolated atrial amyloidosis. BACKGROUND: The expression of ANP and BNP is augmented in the ventricles of failing or hypertrophied hearts, or both. The expression of ANP and BNP in the ventricles of hearts with cardiac amyloidosis, which is hemodynamically similar to restrictive cardiomyopathy, is not yet known. ANP is the precursor protein of isolated atrial amyloid. METHODS: We analyzed the immunohistocytochemical localizations of ANP and BNP as well as the expression of their mRNAs by in situ hybridization in the myocardium and measured the plasma levels of ANP and BNP in patients with cardiac amyloidosis. RESULTS: Four of the five right and all six left ventricular endomyocardial biopsy specimens obtained from six patients with cardiac amyloidosis were immunohistochemically positive for both ANP and BNP; none of the biopsy specimens from eight normal subjects were positive for ANP or BNP. All four of the right atria obtained at operation showed positive immunoreactions for both peptides. Electron microscopy identified specific secretory granules in ventricular myoctyes of the patients with cardiac amyloidosis, but not in ventricular myocytes from the normal control subjects. Double immunocytochemical analysis revealed the co-localization of ANP and BNP in the same granules and that isolated atrial amyloid fibrils were immunoreactive for ANP and BNP, whereas ventricular amyloid fibrils were negative for both peptides. Both ANP mRNA and BNP mRNA were expressed in the ventricles of the patients with cardiac amyloidosis but not in the normal ventricles. The autopsy study of four patients with cardiac amyloidosis revealed an almost transmural distribution of ANP and BNP, with predominance in the endocardial side. Plasma BNP levels in the patients were markedly elevated ([mean +/- SD] 1,165.1+/-561.2 pg/ml) compared with those in the control subjects (8.9+/-6.0 pg/ml, p < 0.05). CONCLUSIONS: Expression of ANP and BNP and their genes was augmented in the ventricular myocytes of the patients with cardiac amyloidosis. Both regional mechanical stress by amyloid deposits and hemodynamic stress by diastolic dysfunction may be responsible for the expression of the peptides in patients with cardiac amyloidosis.

This article has been cited by other articles:

				J. P. Goetze B-Type Natriuretic Peptide: From Posttranslational Processing to Clinical Measurement Clin. Chem., January 1, 2012; 58(1): 83 - 91. [Abstract] [Full Text] [PDF]

				I. A. Paraskevaidis, E. Tsougos, C. Varounis, N. Dagres, D. Karatzas, J. Parissis, and D. T. Kremastinos Exercise-induced changes of B-type natriuretic peptide uncover the unknown coronary artery disease in patients with chest pain and normal left ventricular systolic function European Journal of Cardiovascular Prevention & Rehabilitation, February 1, 2011; 18(1): 72 - 78. [Abstract] [Full Text] [PDF]

				A. Biolo, S. Ramamurthy, L. H. Connors, C. J. O'Hara, H. K. Meier-Ewert, P. T. Soo Hoo, D. B. Sawyer, D. S. Seldin, and F. Sam Matrix Metalloproteinases and Their Tissue Inhibitors in Cardiac Amyloidosis: Relationship to Structural, Functional Myocardial Changes and to Light Chain Amyloid Deposition Circ Heart Fail, November 1, 2008; 1(4): 249 - 257. [Abstract] [Full Text] [PDF]

				J. B. Selvanayagam, P. N. Hawkins, B. Paul, S. G. Myerson, and S. Neubauer Evaluation and Management of the Cardiac Amyloidosis J. Am. Coll. Cardiol., November 27, 2007; 50(22): 2101 - 2110. [Abstract] [Full Text] [PDF]

				S. J. McClure, S. Gall, C. B. Schechter, M. Kearney, and A. G. Zaman Percutaneous Coronary Revascularization Reduces Plasma N-Terminal Pro-B-Type Natriuretic Peptide Concentration in Stable Coronary Artery Disease J. Am. Coll. Cardiol., June 26, 2007; 49(25): 2394 - 2397. [Abstract] [Full Text] [PDF]

				K. B. Shah, Y. Inoue, and M. R. Mehra Amyloidosis and the heart: a comprehensive review. Arch Intern Med, September 25, 2006; 166(17): 1805 - 1813. [Abstract] [Full Text] [PDF]

				F. S. Leya, D. Arab, D. Joyal, K. M. Shioura, B. E. Lewis, L. H. Steen, and L. Cho The Efficacy of Brain Natriuretic Peptide Levels in Differentiating Constrictive Pericarditis From Restrictive Cardiomyopathy J. Am. Coll. Cardiol., June 7, 2005; 45(11): 1900 - 1902. [Abstract] [Full Text] [PDF]

				J. P. Goetze, J. F. Rehfeld, R. Videbaek, L. Friis-Hansen, and J. Kastrup B-type natriuretic peptide and its precursor in cardiac venous blood from failing hearts Eur J Heart Fail, January 1, 2005; 7(1): 69 - 74. [Abstract] [Full Text] [PDF]

				J. P. Goetze Biochemistry of Pro-B-Type Natriuretic Peptide-Derived Peptides: The Endocrine Heart Revisited Clin. Chem., September 1, 2004; 50(9): 1503 - 1510. [Abstract] [Full Text] [PDF]

				A. W. Biondo, E. J. Ehrhart, D. D. Sisson, B. J. Bulmer, H. S. A. De Morais, and P. F. Solter Immunohistochemistry of Atrial and Brain Natriuretic Peptides in Control Cats and Cats with Hypertrophic Cardiomyopathy Veterinary Pathology, September 1, 2003; 40(5): 501 - 506. [Abstract] [Full Text] [PDF]

				G. Palladini, C. Campana, C. Klersy, A. Balduini, G. Vadacca, V. Perfetti, S. Perlini, L. Obici, E. Ascari, G. M. d'Eril, et al. Serum N-Terminal Pro-Brain Natriuretic Peptide Is a Sensitive Marker of Myocardial Dysfunction in AL Amyloidosis Circulation, May 20, 2003; 107(19): 2440 - 2445. [Abstract] [Full Text] [PDF]

				G. M. Bialik, Z. A. Abassi, I. Hammel, J. Winaver, and D. Lewinson Evaluation of Atrial Natriuretic Peptide and Brain Natriuretic Peptide in Atrial Granules of Rats with Experimental Congestive Heart Failure Journal of Histochemistry & Cytochemistry, October 1, 2001; 49(10): 1293 - 1300. [Abstract] [Full Text] [PDF]